Mostrar el registro sencillo del ítem

Artículo

dc.creatorWeersink, Rianne A.es
dc.creatorAlvarez-Alvarez, Ismaeles
dc.creatorMedina-Cáliz, Inmaculadaes
dc.creatorRomero Gómez, Manueles
dc.creatorAmpuero Herrojo, Javieres
dc.creatorRodríguez Seguel, Elisa del Pilares
dc.creatorCuevas, L.es
dc.date.accessioned2022-10-27T16:51:01Z
dc.date.available2022-10-27T16:51:01Z
dc.date.issued2021
dc.identifier.citationWeersink, R.A., Alvarez-Alvarez, I., Medina-Cáliz, I., Romero Gómez, M., Ampuero Herrojo, J., Rodríguez Seguel, E.d.P. y Cuevas, L. (2021). Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old. Clinical Pharmacology & Therapeutics, 109 (4), 1147-1158. https://doi.org/10.1002/cpt.2108.
dc.identifier.issn1532-6535es
dc.identifier.issn0009--9236es
dc.identifier.urihttps://hdl.handle.net/11441/138440
dc.description.abstractOlder patients with hepatotoxicity have been scarcely studied in idiosyncratic drug-induced liver injury (DILI) cohorts. We sought the distinctive characteristics of DILI in older patients across age groups. A total of 882 DILI patients included in the Spanish DILI Registry (33% ≥ 65 years) were categorized according to age: “young” (< 65 years); “young-old” (65–74 years); “middle-old” (75–84 years); and “oldest-old” (≥ 85 years). All elderly groups had an increasingly higher comorbidity burden (P < 0.001) and polypharmacy (P < 0.001). There was a relationship between jaundice and hospitalization (P < 0.001), and both were more prevalent in the older age groups, especially in the oldest-old (88% and 69%, respectively), and the DILI episode was more severe (P = 0.029). The proportion of females decreased across age groups from the young to the middle-old, yet in the oldest-old there was a distinct female predominance. Pattern of liver injury shifted towards cholestatic with increasing age among top culprit drugs amoxicillin-clavulanate, atorvastatin, levofloxacin, ibuprofen, and ticlopidine. The best cutoff point for increased odds of cholestatic DILI was 65 years. Older patients had increased non–liver-related mortality (P = 0.030) as shown by the predictive capacity of the Model for End-Stage Liver Disease score (odds ratio (OR) = 1.116; P < 0.001), and comorbidity burden (OR = 4.188; P = 0.001) in the 6-month mortality. Older patients with DILI exhibited an increasingly predominant cholestatic phenotype across a range of culprit drugs, other than amoxicillin-clavulanate, with increased non–liver-related mortality and require a different approach to predict outcome. The oldest DILI patients exhibited a particular phenotype with more severe DILI episodes and need to be considered when stratifying older DILI populations.es
dc.formatapplication/pdfes
dc.format.extent12 p.es
dc.language.isoenges
dc.publisherWileyes
dc.relation.ispartofClinical Pharmacology & Therapeutics, 109 (4), 1147-1158.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectLiver injuryes
dc.subjectDrug-Inducedes
dc.subjectOlder Patientses
dc.titleClinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-oldes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Biología Celulares
dc.relation.publisherversionhttp://doi.org/10.1002/cpt.2108es
dc.identifier.doi10.1002/cpt.2108es
dc.journaltitleClinical Pharmacology & Therapeuticses
dc.publication.volumen109es
dc.publication.issue4es
dc.publication.initialPage1147es
dc.publication.endPage1158es

FicherosTamañoFormatoVerDescripción
313.pdf334.1KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional